This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech

M&A Boom Keeping Biotech Investors Hungry After Wave of IPOs

  • Tickers in this article:
  • IBB

Biotech companies raised $4.7 billion globally from 68 IPOs during the first half of 2014, and investor appetite will remain strong the rest of the year.

07/31/14 - 04:25 PM EDT

Radius CEO: Osteoporosis Drug on Track Despite Skittish Stock

The recent volatility surrounding Radius Health shares should lessen as the market starts focusing on its osteoporosis drug Abaloparatide, said the company's CEO Robert Ward.

07/31/14 - 02:46 PM EDT

M&A Boom Keeping Biotech Investors Hungry After Wave of IPOs

M&A Boom Keeping Biotech Investors Hungry After Wave of IPOs

  • Tickers in this article:
  • IBB

Biotech companies raised $4.7 billion globally from 68 IPOs during the first half of 2014, and investor appetite will remain strong the rest of the year.

07/31/14 - 04:25 PM EDT

Biotech Valuations Are Low Not Stretched. Here's Why.

Biotech Valuations Are Low Not Stretched. Here's Why.

If biotech companies can assuage concerns about long-term growth, multiples might expand.

07/31/14 - 08:35 AM EDT

Amarin Shocker: There's a Reason to be Bullish Right Now

Amarin Shocker: There's a Reason to be Bullish Right Now

  • Tickers in this article:
  • AMRN

If an FDA appeal decision goes in Amarin's favor, the stock is moving much higher.

07/31/14 - 09:02 AM EDT

Amgen Pleases the Street -- but Will Layoffs Keep Critics at Bay?

Amgen Pleases the Street -- but Will Layoffs Keep Critics at Bay?

Amgen's reallocation of resources is not quieting critics who want a bigger restructuring.

07/30/14 - 11:05 AM EDT

Here's Why Aegerion and Sarepta Trade Higher Wednesday

Here's Why Aegerion and Sarepta Trade Higher Wednesday

Aegerion offers brighter-than-expected sales outlook; Sarepta up on FDA response to petition.

07/30/14 - 11:22 AM EDT

Galectin Drug is a Fatty Liver Flop

Galectin Drug is a Fatty Liver Flop

Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.

07/29/14 - 10:26 AM EDT

Why Gilead Sciences (GILD) Stock Is Up Today

Why Gilead Sciences (GILD) Stock Is Up Today

  • Tickers in this article:
  • GILD

Gilead Sciences (GILD) price target was raised to $127 by analysts at Maxim Group on Monday.

07/28/14 - 11:02 AM EDT

Amgen Shares Have the Right Prescription for Long-Term Growth

Amgen Shares Have the Right Prescription for Long-Term Growth

On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.

07/28/14 - 12:06 PM EDT

CBS Binge-Buys Billboards, Puma Surges & Netflix Subscribers Soar

CBS Outdoor is buying over 1,100 billboards from rival Van Wagner for $690 million in cash.

07/25/14 - 06:00 AM EDT

FDA Rejects AcelRx Painkiller Dispensing Device (Update)

FDA Rejects AcelRx Painkiller Dispensing Device (Update)

  • Tickers in this article:
  • ACRX

AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.

07/28/14 - 09:44 AM EDT

Biotech Stock Mailbag: Intercept Pharma, Inovio

Biotech Stock Mailbag: Intercept Pharma, Inovio

  • Tickers in this article:
  • ICPT
  • INO

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

07/25/14 - 07:31 AM EDT

How Will AbbVie (ABBV) Stock React To Its Second Quarter Earnings Beat?

How Will AbbVie (ABBV) Stock React To Its Second Quarter Earnings Beat?

  • Tickers in this article:
  • ABBV

AbbVie (ABBV) reported second quarter EPS and revenue well ahead of analysts expectations on Friday.

07/25/14 - 10:12 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs